Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results.
Oct 16 (Reuters) — Omeros Corporation: Omeros Corporation Receives Chmp Negative Opinion Following Re-examination Of European Marketing Authorization Application For Narsoplimab In Ta-tma Omeros Corporation - To Terminate Yartemlea Compassionate-use Program In Europe Due To U.s. Demand Omeros Corporation - Plans Clinic
For best results when printing this announcement, please click on link below: Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA Omeros Corporation (Nasdaq: OMER) today announced that the Committee for Medicinal Products f
The EMA’s CHMP issued a negative opinion on Omeros’ marketing authorization application for narsoplimab following re-examination.
The CHMP issued a negative opinion following re-examination of Omeros Corporation’s European marketing authorization application for narsoplimab in TA-TMA.
Omeros Corporation receives a negative opinion from the EMA CHMP on its marketing authorization application for narsoplimab in TA-TMA